Humana Inc (NYSE:HUM) VP Timothy S. Huval sold 1,382 shares of Humana stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total value of $340,027.28. Following the sale, the vice president now owns 11,557 shares of the company’s stock, valued at $2,843,484.28. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Humana Inc (NYSE:HUM) opened at $245.16 on Thursday. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $35,023.58, a PE ratio of 20.92, a P/E/G ratio of 1.68 and a beta of 0.88. Humana Inc has a fifty-two week low of $186.25 and a fifty-two week high of $264.56.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.27 by $0.12. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. Humana’s quarterly revenue was down 3.0% on a year-over-year basis. During the same period last year, the company earned $3.18 earnings per share. analysts anticipate that Humana Inc will post 11.63 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, December 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.65%. Humana’s payout ratio is presently 12.59%.

Humana declared that its board has initiated a share buyback program on Thursday, December 14th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the insurance provider to repurchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board believes its shares are undervalued.

Several large investors have recently bought and sold shares of HUM. Janus Henderson Group PLC boosted its position in Humana by 7,848.8% during the second quarter. Janus Henderson Group PLC now owns 1,567,587 shares of the insurance provider’s stock valued at $377,192,000 after purchasing an additional 1,547,866 shares during the last quarter. FMR LLC boosted its position in Humana by 29.3% during the second quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock valued at $1,571,264,000 after purchasing an additional 1,479,210 shares during the last quarter. Koch Industries Inc. acquired a new position in Humana during the second quarter valued at approximately $404,000. TIAA CREF Investment Management LLC boosted its position in Humana by 39.7% during the second quarter. TIAA CREF Investment Management LLC now owns 1,358,617 shares of the insurance provider’s stock valued at $326,910,000 after purchasing an additional 386,162 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in Humana by 39.8% during the second quarter. Ameriprise Financial Inc. now owns 1,322,413 shares of the insurance provider’s stock valued at $318,216,000 after purchasing an additional 376,177 shares during the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.

Several research analysts have commented on the company. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. ValuEngine upgraded Humana from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Cowen reiterated an “outperform” rating and issued a $275.00 price target (up from $230.00) on shares of Humana in a research report on Wednesday, September 20th. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $273.00 price target on the stock in a research report on Tuesday, October 3rd. Finally, J P Morgan Chase & Co cut Humana from an “overweight” rating to a “neutral” rating and set a $253.00 price target on the stock. in a research report on Monday, October 9th. Twelve research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Humana has an average rating of “Hold” and a consensus price target of $256.30.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/timothy-s-huval-sells-1382-shares-of-humana-inc-hum-stock/1776130.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.